Immunogenicity of One-Dose Quadrivalent Human Papillomavirus Vaccine in Girls
There is now a lot of discussion on less than three doses for Human Papillomavirus (HPV) vaccination and, most probably, the immunity for an “aluminum-only” adjuvanted vaccine would be weaker. The HPV “late” L1 antigen seems to be not of good quality for the quadrivalent vaccine, and therefore L1 should not be a basis for argumentation in favor of a one-dose. We really doubt a “one-dose” proposal to be acceptable for HPV lesion control; certainly, it could be possible for lower response antigens like HPV 18, 11, and 6 with an aluminum-based formulation only. More importantly, the message sugge... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Opinion |
| Erscheinungsdatum: | 2016 |
| Verlag/Hrsg.: |
MedCrave
|
| Schlagwörter: | Human Papillomavirus / Vaccine / Immunogenicity / Adjuvant System 04 / Measles / Mumps / Rubella Cell-Mediated Immunity / Thelper 1-2 / GlaxoSmithKline Biologicals / Rixensart / Belgium / Varicella / Gardasil and Cervarix |
| Sprache: | unknown |
| Permalink: | https://search.fid-benelux.de/Record/base-28939699 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://medcraveonline.com/MOJWH/MOJWH-02-00024.pdf |
There is now a lot of discussion on less than three doses for Human Papillomavirus (HPV) vaccination and, most probably, the immunity for an “aluminum-only” adjuvanted vaccine would be weaker. The HPV “late” L1 antigen seems to be not of good quality for the quadrivalent vaccine, and therefore L1 should not be a basis for argumentation in favor of a one-dose. We really doubt a “one-dose” proposal to be acceptable for HPV lesion control; certainly, it could be possible for lower response antigens like HPV 18, 11, and 6 with an aluminum-based formulation only. More importantly, the message suggested for a one-dose could well be a very bad one as the waning of immunity could have important clinical implications.